Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records-Reference-Cited by-同舟云学术

Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records

Published:2023-09 Issue:9 Volume:11 Page:644-656
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Xie Yan,Bowe Benjamin,Xian Hong,Loux Travis,McGill Janet B,Al-Aly Ziyad^ORCID

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference80 articles.

1. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016;Naghavi;Lancet,2017

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

4. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial;Hernandez;Lancet,2018

5. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes;Holman;N Engl J Med,2017

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors;Communications Medicine;2024-09-11

2. Effect of frailty on effectiveness and safety of GLP-1 receptor agonists versus SGLT2 inhibitors in people with type 2 diabetes in Taiwan: a retrospective, nationwide, longitudinal study;The Lancet Healthy Longevity;2024-09

3. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes;Journal of the American College of Cardiology;2024-09

4. Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study;Diabetes, Obesity and Metabolism;2024-08-22

5. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study;eClinicalMedicine;2024-08